Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

Benzinga Newsdesk www.benzinga.com Positive 85.4%

Neg 0% Neu 0% Pos 85.4%

Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $772 to $780.